매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -32.4% 감소하며 영업이익률이 -155.5%에서 -291.6%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
매출 YoY -32.4% (2023→2024)영업이익률 -155.5%→-291.6%영업CF -8,164→-9,698
Curiox Biosystems
445680 · KOSDAQ₩47,650-1.55%
2026-09-04 closeCuriox Biosystems last closed at ₩47,650 (-1.55%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.27
Distress
Grey
Safe
- Altman Z''
- -0.27
- Beneish M-Score
- -4.03
- Sloan accrual
- 2.28%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -211%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Balance sheetWarning
부채총계 급증 (+346%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업이익률 악화 (-155.5% → -291.6%, -136.1%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 36% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -291.6%
- Interest coverage
- -19.1x
- Return on equity (ROE)
- -16.6%
Operating margin −5pp
Operating lossInterest coverageBase -19.1x adverse case -19.4x
Return on equity (ROE)Base -16.6% adverse case -29.4%
Revenue −15%
Interest coverage riskInterest coverageBase -19.1x adverse case -16.2x
Return on equity (ROE)Base -16.6% adverse case -24.8%
Interest rate +2pp
Interest coverage riskInterest coverageBase -19.1x adverse case -11.7x
Return on equity (ROE)Base -16.6% adverse case -29.9%
Interest coverage limit
Already below the limit by 306.9ppInterest coverage limit at an operating margin of 15.3%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-23Suppliers disclosed by the company in its 2026-03-23 annual report.
Suppliers without disclosed amount
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 김남용17.16%2026-08-10 · 증감 -0.68%p
Connections
AI-extracted related companies · for reference
🔗 See in the full market map →Recent filings
Curiox Biosystems's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Curiox Biosystems
- What technical signals does Curiox Biosystems (445680) have?
- Curiox Biosystems current technical signals: no active technical signal.
- Is Curiox Biosystems a cup-and-handle pattern?
- No. Curiox Biosystems has no valid cup-and-handle signal right now.
- What are Curiox Biosystems's financials and valuation?
- Curiox Biosystems's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy